

CombiGene conducts Extraordinary General Meeting

CombiGene AB (publ) ("CombiGene", the "Company") hereby reminds its shareholders to attend the Extraordinary General Meeting (the "EGM") to be held on December 10, 2024 at 13.30 CET via digital connection. Registration starts at 13.00 CET.

The notice to attend the EGM is available on [CombiGene's web site](#). At the EGM, shareholders will have two different proposals to decide on, one from the Board of CombiGene and one from the largest shareholder of the Company, Strategic Partners A / S. The proposals have been presented in a [press release](#) on October 31 and in a [webinar](#) on November 28 (in Swedish).

Shareholders that wish to participate in the EGM shall be registered in the share register maintained by Euroclear Sweden AB no later than on December 2, 2024 and shall have notified the Company of their intention to participate at the EGM no later than on **December 4, 2024**. Notice to participate shall be given in writing by e-mail to combigene@fredersen.se or by post to CombiGene AB, c/o Fredersen Advokatbyrå, Birger Jarlsgatan 8, SE-114 34 Stockholm. The notice shall contain the shareholder's name, personal identity number or registration number, email address and telephone number and, where applicable, the number of assistants (maximum two).

Contacts

CombiGene AB (publ)
Peter Ekolind, CEO
Phone: +46 (0)8 35 73 55
peter.ekolind@combigene.com

www.combigene.com
CombiGene AB (publ), Skeppsbron 38, SE-111 30 Stockholm, Sweden
+46-8-357355 info@combigene.com

About CombiGene

CombiGene's vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company's Certified Advisor is Västra Hamnen Corporate Finance AB.

Sign up [here](#) to subscribe to Ingeneious News, a newsletter from CombiGene that contains general news and information that is deemed not to have a significant impact on the share price. Ingeneious News is also available at combigene.com.